Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Non-Current Assets (2023 - 2026)

Prelude Therapeutics' Other Non-Current Assets history spans 4 years, with the latest figure at $3.2 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets fell 20.0% to $3.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 million, a 20.0% decrease, with the full-year FY2025 number at $110000.0, changed 0.0% from a year prior.
  • Other Non-Current Assets hit $3.2 million in Q1 2026 for Prelude Therapeutics, up from $110000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for PRLD hit a ceiling of $4.0 million in Q4 2023 and a floor of $110000.0 in Q4 2024.
  • Historically, Other Non-Current Assets has averaged $2.7 million across 4 years, with a median of $3.6 million in 2023.
  • Biggest five-year swings in Other Non-Current Assets: crashed 97.28% in 2024 and later soared 1270.85% in 2025.
  • Tracing PRLD's Other Non-Current Assets over 4 years: stood at $4.0 million in 2023, then crashed by 97.28% to $110000.0 in 2024, then changed by 0.0% to $110000.0 in 2025, then surged by 2840.91% to $3.2 million in 2026.
  • Business Quant data shows Other Non-Current Assets for PRLD at $3.2 million in Q1 2026, $110000.0 in Q4 2025, and $3.2 million in Q3 2025.